Literature DB >> 28280042

No hiding place for BOB inside myeloma.

Hans J Stauss1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28280042      PMCID： PMC5345739          DOI： 10.1182/blood-2017-01-761510

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Nontranscriptional regulation of SYK by the coactivator OCA-B is required at multiple stages of B cell development.

Authors:  Rachael Siegel; Unkyu Kim; Alina Patke; Xin Yu; Xiaodi Ren; Alexander Tarakhovsky; Robert G Roeder
Journal:  Cell       Date:  2006-05-19       Impact factor: 41.582

2.  TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.

Authors:  Lorenz Jahn; Pleun Hombrink; Renate S Hagedoorn; Michel G D Kester; Dirk M van der Steen; Tania Rodriguez; Tsvetelina Pentcheva-Hoang; Arnoud H de Ru; Marjolein P Schoonakker; Miranda H Meeuwsen; Marieke Griffioen; Peter A van Veelen; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Blood       Date:  2017-01-04       Impact factor: 22.113

3.  Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.

Authors:  E Sadovnikova; H J Stauss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

Review 4.  Driving gene-engineered T cell immunotherapy of cancer.

Authors:  Laura A Johnson; Carl H June
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

Review 5.  OCA-B regulation of B-cell development and function.

Authors:  Michael A Teitell
Journal:  Trends Immunol       Date:  2003-10       Impact factor: 16.687
  5 in total
  1 in total

1.  A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies.

Authors:  Sandra Rosskopf; Judith Leitner; Wolfgang Paster; Laura T Morton; Renate S Hagedoorn; Peter Steinberger; Mirjam H M Heemskerk
Journal:  Oncotarget       Date:  2018-04-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.